Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Portfolio Pulse from Vandana Singh
Sanofi has sold the global rights to its rare autoimmune drug Enjaymo to Recordati for $825 million upfront, with potential milestone payments of $250 million. Enjaymo, approved by the FDA in 2022, is expected to see significant revenue growth. The deal is set to close by the end of 2024.
October 04, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi has sold the global rights to Enjaymo to Recordati for $825 million upfront, with additional milestone payments. This move could streamline Sanofi's focus and provide immediate capital.
The sale of Enjaymo rights provides Sanofi with immediate capital and allows it to focus on other strategic areas. The transaction is significant given the upfront payment and potential milestone earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90